Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor–like factor 2 (CRLF2), and other tumors with constitu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Weigert, Oliver, Lane, Andrew A., Bird, Liat, Kopp, Nadja, Chapuy, Bjoern, van Bodegom, Diederik, Toms, Angela V., Marubayashi, Sachie, Christie, Amanda L., McKeown, Michael, Paranal, Ronald M., Bradner, James E., Yoda, Akinori, Gaul, Christoph, Vangrevelinghe, Eric, Romanet, Vincent, Murakami, Masato, Tiedt, Ralph, Ebel, Nicolas, Evrot, Emeline, De Pover, Alain, Régnier, Catherine H., Erdmann, Dirk, Hofmann, Francesco, Eck, Michael J., Sallan, Stephen E., Levine, Ross L., Kung, Andrew L., Baffert, Fabienne, Radimerski, Thomas, Weinstock, David M.
Formato: Artigo
Idioma:Inglês
Publicado em: The Rockefeller University Press 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3280877/
https://ncbi.nlm.nih.gov/pubmed/22271575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20111694
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados